首页|Vonoprazan 10 mg or 20 mg vs.lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis:A randomized controlled trial

Vonoprazan 10 mg or 20 mg vs.lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis:A randomized controlled trial

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Background:Erosive esophagitis(EE)is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus.Proton pump inhibitors are widely used as maintenance therapy for EE,but many patients still relapse.In this trial,we evaluated the noninferiority of vonoprazan vs.lansoprazole as maintenance therapy in patients with healed EE.Methods:We performed a double-blind,double-dummy,multicenter,phase 3 clinical trial among non-Japanese Asian adults with endoscopically confirmed healed EE from April 2015 to February 2019.Patients from China,South Korea,and Malaysia were randomized to vonoprazan 10 mg or 20 mg once daily or lansoprazole 15 mg once daily for 24 weeks.The primary endpoint was endoscopically confirmed EE recurrence rate over 24 weeks with a noninferiority margin of 10％using a two-sided 95％confidence interval(CI).Treatment-emergent adverse events(TEAEs)were recorded.Results:Among 703 patients,EE recurrence was observed in 24/181(13.3％)and 21/171(12.3％)patients receiving vonoprazan 10 mg or 20 mg,respectively,and 47/184(25.5％)patients receiving lansoprazole(differences:-12.3％[95％CI,-20.3％to-4.3％]and-13.3％[95％CI,-21.3％to-5.3％],respectively),meeting the primary endpoint of noninferiority to lansoprazole in preventing EE recurrence at 24 weeks.Evidence of superiority(upper bound of 95％CI＜0％)was also observed.At 12 weeks,endoscopically confirmed EE recurrence was observed in 5/18,2/20,and 7/20 of patients receiving vonoprazan 10 mg,vonoprazan 20 mg,and lansoprazole,respectively.TEAEs were experienced by 66.8％(157/235),69.0％(156/226),and 65.3％(158/242)of patients receiving vonoprazan 10 mg,vonoprazan 20 mg,and lansoprazole,respectively.The most common TEAE was upper respiratory tract infection in 12.8％(30/235)and 12.8％(29/226)patients in vonoprazan 10 mg and 20 mg groups,respectively and 8.7％(21/242)patients in lansoprazole group.Conclusion:Vonoprazan maintenance therapy was well-tolerated and noninferior to lansoprazole for preventing EE recurrence in Asian patients with healed EE.

Erosive esophagitisLansoprazoleMaintenance therapyPotassium-competitive acid blockersVonoprazan

Yinglian Xiao、Jiaming Qian、Shutian Zhang、Ning Dai、Hoon Jai Chun、Chengtang Chiu、Chui Fung Chong、Nobuo Funao、Yuuichi Sakurai、Jessica D.Eisner、Li Xie、Minhu Chen

展开 >

Department of Gastroenterology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510062,China

Department of Gastroenterology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100006,China

Department of Gastroenterology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China

Department of Gastroenterology,Sir Run Run Shaw Hospital,School of Medicine Zhejiang University,Hangzhou,Zhejiang 310020,China

Department of Internal Medicine,Korea University Anam Hospital,Korea University College of Medicine,73 Goryeodae-ro,Seongbuk-gu,Seoul 02841,Republic of Korea

Department of Gastroenterology & Hepatology,Linkou Medical Center,Chang Gung Memorial Hospital,Taoyuan,Taiwan 33353,China

College of Medicine,Chang Gung University,Taoyuan,Taiwan 33353,China

Takeda Development Center Asia,Singapore 018981,Singapore

Hoffmann-La Roche,Basel,4070 Switzerland

Takeda Pharmaceutical Company,Chuo-ku,Osaka 540-8645,Japan

Takeda Pharmaceuticals International Company,Cambridge,MA,02142 USA

Abbott Laboratories,Lake Forest,IL 60045,USA

China Medical Team,Takeda China,Beijing 100027,China

展开 >

2024

10.1097/CM9.0000000000003068

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(8)
  • 27